Search results

NICE is unable to make a recommendation about the use in the NHS of canakinumab drug name (Ilaris) for systemic juvenile idiopathic arthritis..

Type

Technology appraisal guidance

Published

27 November 2013

Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis (RRMS/MS) in adults

Type

Technology appraisal guidance

Last updated

01 June 2014

Evidence-based recommendations on total hip replacement and resurfacing arthroplasty for treating end-stage arthritis of the hip

Type

Technology appraisal guidance

Published

26 February 2014

Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion

Type

Technology appraisal guidance

Published

26 February 2014

Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Type

Technology appraisal guidance

Last updated

26 June 2019

Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma

Type

Technology appraisal guidance

Published

24 April 2013

Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures

Type

Technology appraisal guidance

Published

24 April 2013

NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks

Type

Technology appraisal guidance

Published

24 April 2013

Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion

Type

Technology appraisal guidance

Published

22 May 2013

Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in people with alcohol dependence

Type

Technology appraisal guidance

Published

26 November 2014

Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)

Type

Technology appraisal guidance

Published

26 November 2014

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism

Type

Technology appraisal guidance

Published

17 December 2014

Evidence-based recommendations on infliximab (Remicade, Inflectra, Remsima) adalimumab (Humira) and golimumab (Simponi) for ulcerative colitis after..

Type

Technology appraisal guidance

Published

25 February 2015

Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

Type

Technology appraisal guidance

Published

25 February 2015

Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)

Type

Technology appraisal guidance

Published

23 July 2014

Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults

Type

Technology appraisal guidance

Published

23 July 2014

Evidence-based recommendations on aflibercept (Zaltrap) with FOLFIRI for metastatic colorectal cancer that has progressed after oxaliplatin

Type

Technology appraisal guidance

Published

25 March 2014

Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

Type

Technology appraisal guidance

Published

26 March 2014

Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-TK mutation-positive locally advanced or metastatic non-small-cell lung cancer..

Type

Technology appraisal guidance

Published

23 April 2014

Evidence-based recommendations on bortezomib (Velcade) for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell..

Type

Technology appraisal guidance

Published

23 April 2014

Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy

Type

Technology appraisal guidance

Published

25 March 2015

Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)

Type

Technology appraisal guidance

Published

08 June 2015

Evidence-based recommendations on trastuzumab for treating advanced breast cancer in adults

Type

Technology appraisal guidance

Published

15 March 2002

Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults

Type

Technology appraisal guidance

Last updated

03 March 2017

Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism

Type

Technology appraisal guidance

Published

04 June 2015

Evidence-based recommendations on axitinib (Inlyta) for treating advanced renal cell carcinoma (RCC) (kidney cancer) when prior systemic treatment has failed

Type

Technology appraisal guidance

Published

25 February 2015

NICE is unable to make recommendations about regorafenib for metastatic colorectal cancer because no evidence submission was received from Bayer for the..

Type

Technology appraisal guidance

Published

25 February 2015

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)

Type

Technology appraisal guidance

Published

25 March 2015

Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes

Type

Technology appraisal guidance

Published

25 March 2015

Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

Type

Technology appraisal guidance

Last updated

17 March 2020

Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure

Type

Technology appraisal guidance

Published

25 June 2014

Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes

Type

Technology appraisal guidance

Published

25 June 2014

Evidence-based recommendations on electroconvulsive therapy (ECT) for treating severe depressive illness, mania and catatonia

Type

Technology appraisal guidance

Last updated

01 October 2009

Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure

Type

Technology appraisal guidance

Published

08 January 2020

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults

Type

Technology appraisal guidance

Published

14 August 2019

Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over

Type

Technology appraisal guidance

Published

16 October 2019

NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults

Type

Technology appraisal guidance

Published

30 October 2019

NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib

Type

Technology appraisal guidance

Published

30 October 2019

Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults

Type

Technology appraisal guidance

Published

27 May 2003

Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults

Type

Technology appraisal guidance

Published

19 February 2020

NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals

Type

Technology appraisal guidance

Published

04 March 2020

Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive

Type

Technology appraisal guidance

Published

24 June 2020

Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults

Type

Technology appraisal guidance

Published

07 April 2020

Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

13 May 2020

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months

Type

Technology appraisal guidance

Published

13 May 2020

Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal

Type

Technology appraisal guidance

Published

15 January 2020

Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2

Type

Technology appraisal guidance

Published

12 February 2020

Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults

Type

Technology appraisal guidance

Published

13 February 2020

NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults

Type

Technology appraisal guidance

Published

25 September 2019

NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma

Type

Technology appraisal guidance

Published

25 September 2019